The Swiss Hepatitis C Cohort Study (SCCS)
The Swiss Hepatitis C Cohort Study (SCCS)
复制标题
DOI：
10.1093/ije/dym096
复制
发表时间：
2007-08-01
影响因子：
7.7
通讯作者：
Negro, Francesco
中科院分区：
文献类型：
--
作者：
Prasad, Leonie;Spicher, Virginie Masserey;Negro, Francesco
丙型肝炎病毒以前被归类为“非甲非乙型肝炎病毒”，于 1989 年被发现。1 这种血源性病毒在世界范围内流行，估计有 1.7 亿人慢性感染，约占世界人口的 3%。 2 与持续性丙型肝炎病毒感染相关的长期发病包括肝硬化和原发性肝癌的发展。瑞士丙型肝炎队列研究 (SCCS) 是瑞士病毒性肝炎专家组和瑞士肝脏研究协会的共同努力。 SCCS 的建立是因为基于大规模人群的队列研究是确认或反驳关于慢性丙型肝炎自然病程和丙型肝炎病毒病理学工作假设的唯一方法，部分原因是瑞士人类免疫缺陷病毒队列已经成功建立了专业治疗中心类似合作的经验。 3-9 因此，SCCS 的目标是建立一个基础设施和研究网络，促进丙型肝炎病毒感染自然史的临床和生物医学研究，并优化和规范丙型肝炎病毒感染患者的管理和治疗。该队列预计将增加有关丙型肝炎病毒感染进展因素的信息，从而为未来的治疗决策和丙型肝炎病毒相关疾病在人口层面的负担预测提供信息，并补充瑞士联邦公共卫生办公室强制性国家监测系统收集的流行病学数据。数据收集获得了每家医院伦理委员会的伦理批准。SCCS 的招募于 2000 年 9 月开始，初始资金来自瑞士病毒性肝炎专家组。自2001年4月以来，核心结构的资金主要由瑞士国家科学基金会提供。多年来，包括瑞士教育和科学办公室以及欧盟委员会在内的多个公共和私人机构为核心结构和科学嵌套项目提供了额外的资金来源。
The hepatitis C virus, formerly classified as ‘non-A non-B’hepatitis virus, was identified in 1989. 1 This blood-borne virus is endemic worldwide, with an estimated 170 million persons chronically infected, representing approximately 3% of the world population. 2 Long-term morbidity associated with persistent hepatitis C virus infection includes the development of cirrhosis and primary liver cancer. The Swiss Hepatitis C Cohort Study (SCCS) is a joint effort between the Swiss Group of Experts in Viral Hepatitis and the Swiss Association for the Study of the Liver. The SCCS was established because large population-based cohort studies are the only way to confirm or refute working hypotheses on the natural course of chronic hepatitis C and on hepatitis C virus pathology, and partly because experience with a similar collaborative effort of specialized treatment centres had already been successfully established for a human immunodeficiency virus cohort in Switzerland. 3–9 Therefore, the aims of the SCCS were to set up an infrastructure and investigative network fostering clinical and biomedical research on the natural history of hepatitis C virus infection and to optimize and standardize the management and treatment of hepatitis C virus-infected patients. The cohort is expected to add information on factors that shape progression of hepatitis C virus infection, thus informing future therapeutic decisions and predictions of the burden of hepatitis C virus-related diseases at the population level, as well as supplementing epidemiological data collected by the mandatory national surveillance system at the Swiss Federal Office of Public Health. Ethical approval for data collection was obtained from each hospital’s ethics committee.Recruitment for the SCCS began in September 2000, with initial funding from the Swiss Group of Experts in Viral Hepatitis. Since April 2001, funding of the core structure has been largely provided by the Swiss National Science Foundation. Additional sources of funding, for both the core structure and the scientific nested projects, have been provided over the years by several public and private institutions, including the Swiss Office for Education and Science and the European Commission.